

INFECTION CONTROL

The logo consists of the lowercase letters 'i' and 'c' in a bold, serif font. The 'i' is positioned to the left of the 'c', and they are both rendered in a dark, solid color.

EDITORIAL

The Drainage Bag Additive Saga

Calvin M. Kunin, MD

ORIGINAL ARTICLES

Evaluation of H₂O₂ Prophylaxis of Bacteriuria in Patients with Long-Term Indwelling Foley Catheters: A Randomized Controlled Study

Donna E. Sweet, MD; Hewitt C. Goodpasture, MD, FACP; Katherine Holl, RN; Sharon Smart, RN; Holly Alexander, PhD; Ahmad Hedari

A Comparison of Pneumonia Caused by Gentamicin, Methicillin-Resistant and Gentamicin, Methicillin-Sensitive *Staphylococcus aureus*: Epidemiologic and Clinical Studies

Joseph R. Lentino, MD, PhD, FACP; Hani Hennein, MS; Sally Krause, RN; Sharon Pappas, BSN; Gail Fuller, BSN; Doris Schaaff, MD; Mary Beth DiCostanzo, BS

Evidence for the Non-Infectious Etiology of Early Postoperative Fever

Richard A. Garibaldi, MD; Susan Brodine, RN; Sego Matsumiya, RN; Miki Coleman, MS

Readers' Forum: Nosocomial Fungal Infection During Hospital Renovation

Keith Krasinski, MD; Robert S. Holzman, MD; Bruce Hanna, PhD; M. Alba Greco, MD; Michael Graff, MD; Madhu Bhogal, MD

Topics in Clinical Microbiology: The Rapidly Growing Mycobacteria—*Mycobacterium fortuitum* and *Mycobacterium chelonae*

Timothy H. Brown, MD

Product Commentary: Selection of Closed Urinary Drainage Systems—An Update

Inge Gurevich, RN, MA, CIC



WHAT'S THE BEST HANDWASH/SCRUB? HANDS UP OR HANDS DOWN IT'S

HIBICLENS[®]

(CHLORHEXIDINE GLUCONATE)

It is well established that hand-washing is the most important single procedure in preventing transmission of hospital-acquired infections. HIBICLENS, the only proven antiseptic/antimicrobial, is the best agent available for both personnel handwashing and surgical scrubbing. HIBICLENS

provides the most immediate and prolonged protection against infection, with the best bactericidal "kill rate." And to encourage skin cleansing among hospital personnel, HIBICLENS offers cosmetic acceptability coupled with an excellent safety profile. Gentle to the skin, HIBICLENS is virtually

nonirritating and nonsensitizing, with a low potential for toxicity.

Available as both a liquid and impregnated in a disposable Sponge/Brush, HIBICLENS remains the single most effective antiseptic/antimicrobial skin cleanser for use throughout the hospital.

THE BEST ANTISEPTIC/ANTIMICROBIAL SKIN CLEANSER



STUART PHARMACEUTICALS
Division of ICI Americas Inc.
Wilmington, Delaware 19897

INFECTION CONTROL®

Table of Contents

Editorial

- The Drainage Bag Additive Saga** 261
Calvin M. Kunin, MD

Original Articles

- Evaluation of H₂O₂ Prophylaxis of Bacteriuria in Patients with Long-Term Indwelling Foley Catheters: A Randomized Controlled Study** 263
Donna E. Sweet, MD; Hewitt C. Goodpasture, MD, FACP; Katherine Holl, RN; Sharon Smart, RN; Holly Alexander, PhD; Ahmad Hedari

- A Comparison of Pneumonia Caused by Gentamicin, Methicillin-Resistant and Gentamicin, Methicillin-Sensitive *Staphylococcus aureus*: Epidemiologic and Clinical Studies** 267
Joseph R. Lentino, MD, PhD, FACP; Hani Hennein, MS; Sally Krause, RN; Sharon Pappas, BSN; Gail Fuller, BSN; Doris Schaaff, MD; Mary Beth DiCostanzo, BS

- Evidence for the Non-Infectious Etiology of Early Postoperative Fever** 273
Richard A. Garibaldi, MD; Susan Brodine, RN; Sego Matsumiya, RN; Miki Coleman, MS

- Readers' Forum: Nosocomial Fungal Infection During Hospital Renovation** 278
Keith Krasinski, MD; Robert S. Holzman, MD; Bruce Hanna, PhD; M. Alba Greco, MD; Michael Graff, MD; Madhu Bhogal, MD

- Topics in Clinical Microbiology: The Rapidly Growing Mycobacteria—*Mycobacterium fortuitum* and *Mycobacterium chelonae*** 283
Timothy H. Brown

- Product Commentary: Selection of Closed Urinary Drainage Systems—An Update** 289
Inge Gurevich, RN, MA, CIC

Departments

- Letters to the Editor** 259 **Calendar of Events** 291

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control (ISSN-0195-9417) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: Thorofare (609) 848-1000.

Copyright 1985: All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

Subscriptions: Subscription requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Scope Incorporated, Mansui Bldg. 9-18, Kanda Surugadai 2-chome, Chiyoda-ku, Tokyo 101, Japan. Annual subscription price is: Individual: One year—\$35.00; Two years—\$60.00; Three years—\$75.00. Institutional: One year—\$50.00; Two years—\$75.00; Three years—\$90.00. All subscriptions, without exception, will start with the first issue published after the order is received. Back copies are available, but must be purchased separately. Cost per individual copy is \$7.00. Foreign subscribers add \$15.00 to regular rate; foreign orders, \$8.00.

Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086.
Postmaster: Form 3547 to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.

Safe for Scopes



HEPATITIS

Sporicidin, diluted 1:16, inactivates the Hepatitis B Virus in 10 minutes.

(Centers for Disease Control, Phoenix, Arizona)

Completely disinfects flexible and rigid scopes in 10 minutes with only 0.13% glutaraldehyde.

Safe to use . . . Does not cloud scope lenses nor harm metals, rubber and/or plastics. Does not stain or irritate the hands. No gloves are necessary for safety. Vapors do not irritate the eyes or nostrils.

Most effective . . . The only sterilizing solution which is fully effective against the tubercle bacillus, influenza, hepatitis and enteroviruses when diluted 1 in 16.

Stable . . . Fully effective for 30 days after activation.

Proven . . . The most effective cold sterilant and disinfectant ever registered by the E.P.A.

“Sporicidin, diluted 1 in 16, (0.13% glutaraldehyde), is effective for high level hospital disinfection . . .”

*Centers for Disease Control, Atlanta, GA
(Guidelines . . . revised August 1982)*

“This study has determined that although E.P.A. requirements for classifying a sterilizing agent were satisfied by Cidex, they were exceeded by Sporicidin.”

*Journal of Dental Research, Vol. 60, March 1981
(U.S. Army Institute of Dental Research, Wash., DC)*

“Sporicidin . . . was both more stable and more active against test spores than . . . Cidex and Cidex-7.”

Infection Control, 1(2): 90-93, 1980



The Sporicidin Company

4000 Massachusetts Avenue, NW, Washington, DC 20016 Call Toll Free (800) 424-3733

EDITOR

Richard P. Wenzel, MD
Charlottesville, Virginia

SENIOR ASSOCIATE EDITOR

William Schaffner, MD
Nashville, Tennessee

ASSOCIATE EDITORS

Sue Crow, RN, MSN
Shreveport, Louisiana

John E. McGowan, Jr., MD
Atlanta, Georgia

Dennis G. Maki, MD
Madison, Wisconsin



SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086

Publisher
Richard N. Roash

Associate Publisher
Eric Baloff

Managing Editor
Donna Carpenter

Assistant Editor
M. Lynne Stanwood

Circulation Manager
Kevin J. Fenton

Advertising Manager
Randall Roash

**Classified
Advertising Representative**
Lorraine Giles

EDITORIAL ADVISORY BOARD

Robert C. Aber, MD
Hershey, Pennsylvania

Charles S. Bryan, MD
Columbia, South Carolina

John P. Burke, MD
Salt Lake City, Utah

Marie B. Coyle, PhD
Seattle, Washington

Burke A. Cunha, MD
Mineola, New York

Richard E. Dixon, MD
Trenton, New Jersey

Harvey A. Elder, MD
Loma Linda, California

Bruce Farber, MD
Pittsburgh, Pennsylvania

Peter C. Fuchs, MD, PhD
Portland, Oregon

Richard A. Garibaldi, MD
Farmington, Connecticut

Donald A. Goldmann, MD
Boston, Massachusetts

Dieter H.M. Gröschel, MD
Charlottesville, Virginia

Peter A. Gross, MD
Hackensack, New Jersey

Karen Hadley, RN, MPH
New Orleans, Louisiana

David K. Henderson, MD
Bethesda, Maryland

Peter N.R. Heseltine, MD
Los Angeles, California

Cyrus C. Hopkins, MD
Boston, Massachusetts

Allen B. Kaiser, MD
Nashville, Tennessee

Harold Laufman, MD, PhD
New York, New York

William J. Ledger, MD
New York, New York

Barbara McArthur, RN, PhD
Detroit, Michigan

Rob Roy MacGregor, MD
Philadelphia, Pennsylvania

C. Glen Mayhall, MD
Richmond, Virginia

Ronald Lee Nichols, MD
New Orleans, Louisiana

Harry C. Nottebart, Jr., JD, MD
Richmond, Virginia

James E. Peacock, Jr., MD
Winston-Salem, North Carolina

Frank S. Rhame, MD
Minneapolis, Minnesota

William A. Rutala, PhD, MPH
Chapel Hill, North Carolina

William E. Scheckler, MD
Madison, Wisconsin

Robert J. Shannon, MSPH
Boston, Massachusetts

Walter E. Stamm, MD
Seattle, Washington

Charles W. Stratton, MD
Nashville, Tennessee

Timothy R. Townsend, MD
Baltimore, Maryland

William M. Valenti, MD
Rochester, New York

James Veazey, MD
Albany, New York

Kathy J. Wydra, RN
Geneva, New York

FOREIGN ADVISORY BOARD

Graham Ayliffe, MD, FRC Path.
Birmingham, England

Professor G. Berencsi
Szeged, Hungary

Professor Jaap Dankert
Groningen, Netherlands

Professor Dr. F. Daschner
Freiburg, West Germany

Lars O. Kallings, MD
Stockholm, Sweden

Professor W.B. Kędzia
Sieroca, Poland

Professor A.P. Krasilnikow
Minsk, USSR

Professor Dr. W. Marget
Munich, West Germany

Bertil Nyström, MD
Huddinge, Sweden

Ian Phillips, MA, MD, MRC Path.
London, England

Samuel Ponce de Leon, MD
Mexico City, Mexico

Hans Reber, MD
Basel, Switzerland

Professor Gerald Reybrouck
Leuven, Belgium

Manfred L. Rotter, MD, DipBact
Vienna, Austria

Theodore Sacks, MD
Jerusalem, Israel

Dr. Bernhard M. Thimm
Federal Republic of Germany

Professor Dr. med. H.P. Werner
Mainz, West Germany

Professor Dr. W. Weuffen
Greifswald, German Democratic Republic



RABIES VACCINE (HUMAN DIPLOID CELL) U.S.P. **IMOVAX® RABIES**

DESCRIPTION: The IMOVAX RABIES Vaccine produced by Institut Merieux is a sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA.

The virus is harvested from infected human diploid cells, MRC-5 strain, concentrated by ultrafiltration and is inactivated by beta propiolactone. One dose of reconstituted vaccine contains less than 100 mg albumin, less than 150 µg neomycin sulfate and 20 µg of phenol red indicator. The vaccine is for intramuscular use.

The vaccine contains no preservative or stabilizer. It should be used immediately after reconstitution.

The potency of Merieux IMOVAX RABIES Vaccine is equal to or greater than 2.5 international units of rabies antigen.

CONTRAINDICATIONS: For post-exposure treatment there are no known specific contraindications to the use of Merieux IMOVAX RABIES Vaccine. In cases of pre-exposure immunization, there are no known specific contraindications other than situations such as developing febrile illness, etc.

WARNINGS: In both pre-exposure and post-exposure immunization, the full 1.0 ml dose should be given intramuscularly.

In the case of pre-exposure immunization, recently a significant increase has been noted in "immune complex-like" reactions in persons receiving booster doses of HDCV.¹ The illness characterized by onset 2-21 days post-booster, presents with a generalized urticaria and may also include arthralgia, arthritis, angioedema, nausea, vomiting, fever, and malaise. In no cases were the illnesses life-threatening. Preliminary data suggest this "immune complex-like" illness may occur in up to 6% of persons receiving booster doses and much less frequently in persons receiving primary immunization. Additional experience with this vaccine is needed to define more clearly the risk of these adverse reactions.^{2,3}

Two cases of neurologic illness resembling Guillain-Barré syndrome^{3,4} a transient neuromyolytic illness, that resolved without sequelae in 12 weeks and a focal subacute central nervous system disorder temporally associated with HDCV, have been reported.⁵

All serious systemic neuromyolytic or anaphylactic reactions to a rabies vaccine should be immediately reported to the state health department or the Division of Viral Diseases,

Center for Infectious Diseases, CDC, 404-329-3095 during working hours, or 404-329-2888 at other times.²

PRECAUTIONS: General—When a person with a history of hypersensitivity must be given rabies vaccine, antihistamines may be given; epinephrine (1:1000) should be readily available to counteract anaphylactic reactions, and the person should be carefully observed after immunization.

While the concentration of antibiotics in each dose of vaccine is extremely small, persons with known hypersensitivity to any of these agents could manifest an allergic reaction. While the risk is small, it should be weighed in light of the potential risk of contracting rabies.

Drug Interactions—Corticosteroids, other immunosuppressive agents, and immunosuppressive illnesses can interfere with the development of active immunity and predispose the patient to developing rabies. Immunosuppressive agents should not be administered during post-exposure therapy, unless essential for the treatment of other conditions. When rabies post-exposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, it is especially important that serum be tested for rabies antibody to ensure that an adequate response has developed.²

Usage in Pregnancy—Pregnancy Category C. Animal reproduction studies have not been conducted with IMOVAX RABIES Vaccine. It is also not known whether the product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Rabies vaccine should be given to a pregnant woman only if clearly needed.

Because of the potential consequences of inadequately treated rabies exposure and limited data that indicate that fetal abnormalities have not been associated with rabies vaccination, pregnancy is not considered a contraindication to post-exposure prophylaxis.^{2,7} If there is substantial risk of exposure to rabies, pre-exposure prophylaxis may also be indicated during pregnancy.²

Pediatric Use—Both safety and efficacy in children have been established.

ADVERSE REACTIONS: Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild systemic adverse reactions to rabies vaccine. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents (e.g. aspirin).

Reactions after vaccination with HDCV are less common than with previously available vaccines.^{1,3,4} In a study

using five doses of HDCV, local reactions, such as pain, erythema, and swelling or itching at the injection site were reported in about 25% of recipients of HDCV, and mild systemic reactions such as headache, nausea, abdominal pain, muscle aches and dizziness were reported in about 20% of recipients.²

Serious systemic anaphylactic or neuromyolytic reactions occurring during the administration of rabies vaccines pose a dilemma for the attending physician. A patient's risk of developing rabies must be carefully considered before deciding to discontinue vaccination. Moreover, the use of corticosteroids to treat life-threatening neuromyolytic reactions carries the risk of inhibiting the development of active immunity to rabies. It is especially important in these cases that the serum of the patient be tested for rabies antibodies. Advice and assistance on the management of serious adverse reactions in persons receiving rabies vaccines may be sought from the state health department or CDC.²

REFERENCES:

1. CDC. Systemic allergic reactions following immunization with human diploid cell rabies vaccine. *MMWR* 33:185-7 (1984)
2. CDC. Recommendations of the Immunization Practices Advisory Committee (ACIP). Rabies Prevention—United States, 1984. *MMWR* 33:393-402, 407-8 (1984)
3. Rubin, Hattwick MAW, Jones S, Gregg MB, Schwartz VD. Adverse reactions to duck embryo rabies vaccine. *Ann Intern Med* 78:643-9 (1973)
4. Boe E, Nyland H. Guillain-Barré syndrome after vaccination with human diploid cell rabies vaccine. *Scand J Infect Dis* 12:231-2 (1980)
5. CDC. Adverse reactions to human diploid cells rabies vaccine. *MMWR* 29:609-10 (1980)
6. Bernard KW, Smith PW, Kader FJ, Moran MJ. Neuromyolytic illness and human diploid cell rabies vaccine. *JAMA* 248:3136-8 (1982)
7. Varner MW, McGuinness GA, Galask RP. Rabies vaccination in pregnancy. *Am J Obstet Gynecol* 143:717-8 (1982)
8. Greenberg M, Childress J. Vaccination against rabies with duck embryo and Semple vaccines. *JAMA* 173:333-7 (1960)

RABIES IMMUNE GLOBULIN (HUMAN) U.S.P. **IMOGAM® RABIES**

DESCRIPTION: Rabies Immune Globulin (Human) IMOGAM® RABIES is a sterile solution of antirabies immunoglobulin (10-18% protein) for intramuscular administration. It is prepared by cold alcohol fractionation from pooled venous plasma of individuals immunized with Rabies Vaccine prepared from human diploid cells (HDCV). The product is stabilized with 0.3 M glycine and contains 1:10,000 sodium ethylmercurithiosalicylate (thimerosal) as a preservative. The globulin solution has a pH of 6.8 ± 0.4 adjusted with sodium hydroxide or hydrochloric acid. The product is standardized against the U.S. Standard Rabies Immune Globulin. The U.S. unit of potency is equivalent to the International Unit (I.U.) for rabies antibody. The product is prepared from units of human plasma that have been tested and found negative for hepatitis B surface antigen (HBsAg) by FDA-required tests.

CONTRAINDICATIONS: Rabies Immune Globulin (Human) should not be administered in repeated doses once vaccine treatment has been initiated. Repeating the dose may interfere with maximum active immunity expected from the vaccine.

WARNINGS: Rabies Immune Globulin (Human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations or those individuals allergic to thimerosal.

Persons with specific IgA deficiency have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products containing IgA.^{1,2}

PRECAUTIONS: General—Rabies Immune Globulin (Human) should not be administered intravenously because of the potential for serious reactions. Injection should be made intramuscularly and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel. Although systemic reactions to immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactoid symptoms. As with all preparations given intramuscularly, bleeding complications may be encountered in patients with bleeding disorders.

Drug Interactions—Live virus vaccines such as measles vaccines should not be given close to the time of Rabies Immune Globulin (Human) administration because antibodies in the globulin preparation may interfere with the immune response to the vaccination. Immunization with live vaccines should not be given within three months after Rabies Immune Globulin (Human) administration.

Pregnancy Category C—Animal reproduction studies have not been conducted with Rabies Immune Globulin (Human). It is also not known whether RIG(H) can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. RIG(H) should be given to a pregnant woman only if clearly needed.

ADVERSE REACTIONS: Local or mild systemic adverse reactions to the globulin after intramuscular injections are uncommon^{3,4} and may be treated symptomatically. Local tenderness, soreness or stiffness of the muscles may occur at the injection site and may persist for several hours after injection. Urticaria and angioedema may occur. Anaphylac-

tic reactions, although rare, have been reported following injection of human immune globulin preparations.

REFERENCES:

1. Fudenberg H.H. Sensitization to immunoglobulins and hazards of gamma globulin therapy, pp 211-220 in Merler E., Editor, Immunoglobulins: biologic aspects and clinical uses. National Academy of Sciences, Wash., D.C., 1970.
 2. Pineda A.A. and Taswell H.F. Transfusion reactions associated with anti-IgA antibodies: Report of four cases and review of the literature. *Transfusion* 15:10-15 (1975).
 3. Janeway C.A., Rosen F.S. The gamma globulins. IV. Therapeutic uses of gamma globulins. *N Engl J Med* 275:826-831 (1966).
 4. Kjellman H. Adverse reactions to human immune serum globulin in Sweden (1969-1978) pp 143-150. Immunoglobulins: Characteristics and uses of intravenous preparations. Alving B.M. and Finlayson J.S., Editors. U.S. Dept. Health & Human Services, DHHS Publ. No. (FDA) 80-9005, Wash., D.C., 1980.
- Issued January, 1984

Manufactured by: INSTITUT MERIEUX
Lyon-France, U.S. License No. 384

Distributed by: MERIEUX INSTITUTE, INC.
Miami, Florida 33126
800-327-2842, (305) 593-9577

 MERIEUX INSTITUTE USA